Fig. 2: Prognostic value of mass spectrometry at defined time points. | Blood Cancer Journal

Fig. 2: Prognostic value of mass spectrometry at defined time points.

From: Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Fig. 2: Prognostic value of mass spectrometry at defined time points.

Progression-free (PFS) and overall survival (OS) of GMMG-MM5 patients stratified by the mass spectrometry test result (negative/positive) after induction therapy (A + B), prior to maintenance therapy/observation (C + D) and after one year of maintenance treatment/observation (E + F). PFS and OS times were measured from the respective landmarks.

Back to article page